Vitamin D Supplementation on Metabolic Syndrome Indicators Among Older Adults, Alborz Province, Iran

Vitamin D Supplementation on Metabolic Syndrome Indicators Among Food Insecure, Vitamin D Deficient Older Adults in Karaj City, Alborz Province, Iran;

General objective: To assess the effect of vitamin D supplementation on metabolic syndrome among food insecure and vitamin D deficient older adults in Karaj city, Alborz province in Iran. A two-arm randomised controlled trial (RCT) will be conducted by recruiting participants. Inclusion Criteria: Food insecure, metabolic syndrome; Vitamin D deficiency Exclusion Criteria: those who are already taking any type of vitamin D supplements, Individuals with a history of allergy, Those subjects with serious medical condition such as cancer, heart attack, stroke, and etc., Intervention group: The intervention will start from 10 of May 2017 to 11 of July 2017 for 2 months. The intervention group will receive 50,000 U vitamin D3 per week (equivalent to 1,250 μg) for 8 weeks plus pamphlets and brochures about nutrition and health at the beginning of the study. Control group: The respondents in control group will receive placebo plus brochures and pamphlets related to nutrition and health at the beginning of the study. The data collection process will identify the older adults for both groups; intervention and control. Consent will be obtained from those who are eligible. Anthropometric measurement (height, weight, body mass index, and waist circumference), blood pressure measurement, blood taking and three-day food record will be obtained during baseline from all study respondents in the intervention and control groups. Primary Output: Achieving 25 (OH) D upper than insufficient serum 25(OH) D level >30 ng/l. Secondary Output: Reduction anthropometry (body mass index (BMI) and waist circumference (WC), Improved Biomarkers indicators (lipid profile, fasting blood fast), improved blood pressure before and after intervention.

Study Overview

• Status: Completed
• Conditions: Hypertension; Diabetes Mellitus; Vitamin D Deficiency; Lipid Metabolism Disorders; Obesity, Abdominal
• Intervention / Treatment: Drug: D-vitin, soft gelatin capsule (vitamin D3,50000 IU); Drug: Placebo vitamin D3

Detailed Description

This study aims to find relationships between food insecurity, vitamin D intakes and its impact on metabolic syndrome among older adults in a city in Alborz province in Iran, known as Karaj. This study has 2 parts; the first part is to determine the prevalence of food insecurity and vitamin D deficiency among older adults in Karaj city. The second part is an intervention study examining effects of vitamin D supplementation on metabolic syndrome (diabetes, obesity, hypertension, and dyslipidaemia) among older adults who have at least have risk factors of metabolic syndrome, food insecure and vitamin D deficient. The first part; the data collection process will be performed in a few stages. The first stage will be to initiate contacting with the health centres in Karaj city to identify the older adults. Appointments will be set after screening the study subjects who will be eligible. Consent will be obtained from those who were eligible. The preliminary information on demographic data, socioeconomics, food insecurity, dietary intake and sunlight exposure will be collected by using a set of questionnaires. The blood sample for measuring serum 25 (OH) D will be taken the same day as questionnaires were filled.

The second stage: The data collection process will be performed in few stages. The first stage will include of contact with health centres in Karaj city to identify the older adults for both groups; intervention and control. Consent will be obtained from those who will eligible. Anthropometric measurement (height, weight, body mass index, and waist circumference), blood pressure measurement, blood taking and three-day food record will be obtained during baseline from all study respondents in the intervention and control groups.

• Study Type: Interventional
• Enrollment (Actual): 120
• Phase: Phase 2

Contacts and Locations

Study Locations

• Iran, Islamic Republic of
  • Alborz
    • Karaj, Alborz, Iran, Islamic Republic of
      • Maryam Zarei

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 60 years to 80 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Food insecure,
• Have fit criteria of metabolic syndrome; (WC>90 cm), obesity (BMI≥30 kg/m2), diabetes (FBS>100 mg/dl), high blood pressure (systolic >135 mmHg and diastolic >85 mmHg) and dyslipidaemia (LDL≥ 240 mg/dl, HDL<40 mg/dl, TC≥ 160 mg/dl; TG≥ 200 mg/dl),
• Vitamin D deficient; serum 25(OH) D level <30 ng/ml,
• No use of vitamin D supplementation before 60 days,

Exclusion Criteria:

• An inability or unwillingness to participate,
• Those who are already taking any type of vitamin D supplements,
• Individuals with a history of allergy,
• Those subjects with serious medical condition such as cancer, heart attack, stroke, and etc.,
• Illness that required corticosteroids or insulin,
• Drugs are known to influence vitamin D level; steroids, anti-acids, oestrogen,
• People with conditions that contradict vitamin D supplementation, for example, a history of hypercalcaemia, hepatic disease or renal stones, sarcoidosis, or malignancy,

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: Intervention group; Intervention group will receive 50,000 U vitamin D3 per week (equivalent to 1,250 μg) for 8 weeks	Drug: D-vitin, soft gelatin capsule (vitamin D3,50000 IU); Intervention group: The respondents in intervention group will receive 50000 vitamin D for 8 weeks. Plus, brochures and pamphlets related to nutrition and health.; Other Names: cholecalciferol,
PLACEBO_COMPARATOR: control group; Control group will receive vitamin D as a placebo. placebo will be identical in appearance taste and odourless.	Drug: Placebo vitamin D3; vitamin D as a placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Achieving 25 (OH) D upper than insufficient serum 25(OH) D level >30 ng/l.	According to the guidline, vitamin D deficiency will improve by taking vitamin D3 by 2 months.	by 2 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Reduction anthropometry (BMI and WC),	Reduction of BMI, WC after 2 months intervention by vitamin D3	by 2 months
Improved Biomarker indicators (lipid profile)	Reduction of lipid profiles are important for this research after vitamin D3 intervention.	by 2 months
Improved Biomarker indicator FBS	Reduction of FBS by 2 months intervention via taking vitamin D	by 2 months
Improved blood pressure	Reduction of blood pressure after taking vitamin D for 2 months	by 2 months

Collaborators and Investigators

• Sponsor: Alborz Medical University
• Collaborators: Universiti Putra Malaysia
• Investigators: Principal Investigator: Zarei, World Health Organization

Study record dates

Study Major Dates

• Study Start (ACTUAL): February 10, 2017
• Primary Completion (ACTUAL): May 10, 2017
• Study Completion (ACTUAL): July 10, 2017

Study Registration Dates

• First Submitted: June 13, 2017
• First Submitted That Met QC Criteria: June 20, 2017
• First Posted (ACTUAL): June 21, 2017

Study Record Updates

• Last Update Posted (ACTUAL): January 16, 2018
• Last Update Submitted That Met QC Criteria: January 12, 2018
• Last Verified: January 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Overnutrition; Nutrition Disorders; Insulin Resistance; Hyperinsulinism; Avitaminosis; Deficiency Diseases; Malnutrition; Obesity; Metabolic Syndrome; Vitamin D Deficiency; Metabolic Diseases; Lipid Metabolism Disorders; Obesity, Abdominal; Physiological Effects of Drugs; Micronutrients; Bone Density Conservation Agents; Calcium-Regulating Hormones and Agents; Vitamin D; Cholecalciferol; Vitamins; Ergocalciferols
• Other Study ID Numbers: Abzums.Rec.1395.114

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No